Template:Plasma estrogen levels after a single dose of estradiol by different routes
Appearance
Route | Dose (mg) |
Time measured |
(pg/mL) |
(pg/mL) |
E2:E1 ratio |
Ref | |||
---|---|---|---|---|---|---|---|---|---|
Oral |
1 2 4 |
12 h 3 h 6 h |
+25 +40 +50 |
+150 +250 +500 |
0.15 0.16 0.10 |
[1] [1] [1] | |||
Sublingual |
1 0.5 0.5 0.5 |
1 h 1 h 1 h 1 h |
+450 +250 +750 +75 |
+160 +85 +250 +24 |
3 3 3 3 |
[2] [2] [3] [4] | |||
Intranasal | 1 | 1 h | +110 | +110 | 1.0 | [5] | |||
Topical (gel) |
3 3/d 3/2 d |
5 h 12–20 h 12 h 36 h |
+70 +45–279 +300–1310 +20–179 |
+50 +31–230 +24–110 +120–500 |
0.4 1 1 1 |
[6] [7] [7] [7] | |||
Vaginal (cream) | 0.5 1.0 |
3 h 3 h |
+830 +800 |
+150 +150 |
5.0 5.0 |
[8] [5] | |||
Rectal | 1 | 3 h | +620 | +120 | 5.0 | [9] | |||
Intramuscular inj. (oil soln.) |
EB : 5 EV : 5 EC : 5 EU : 100 PEP : 320 |
1.8, 2.4 da 2.2, 2.7 da 3.9, 5.1 da 1 d 16, 25 da |
940b 667b 338b 500b 270b |
343b 324b 145b ND 1000b |
2.7 2.1 2.3 ND 0.27 |
[10] [10] [10] [11] [12] | |||
Intravenous inj. | 0.3 | 5 min | 8321b | 960b | 8.7 | [13] | |||
Footnotes: a = Tmax for E2, E1 levels. b = Actual levels (not change). Sources: Main: [14] |
See also[edit]
References[edit]
- ^ a b c Dada OA, Laumas V, Landgren BM, Cekan SZ, Diczfalusy E (1978). "Effect of graded oral doses of oestradiol on circulating hormonal levels". Acta Endocrinol. 88 (4): 754–67. doi:10.1530/acta.0.0880754. PMID 581116.
- ^ a b Price TM, Blauer KL, Hansen M, Stanczyk F, Lobo R, Bates GW (March 1997). "Single-dose pharmacokinetics of sublingual versus oral administration of micronized 17 beta-estradiol". Obstet Gynecol. 89 (3): 340–5. doi:10.1016/S0029-7844(96)00513-3. PMID 9052581.
- ^ Burnier AM, Martin PL, Yen SS, Brooks P (May 1981). "Sublingual absorption of micronized 17beta-estradiol". Am. J. Obstet. Gynecol. 140 (2): 146–50. doi:10.1016/0002-9378(81)90101-0. PMID 6786097.
- ^ Fiet J, Hermano M, Witte J, Villette JM, Haimart M, Gourmel B, Tabuteau F, Rouffy J, Dreux C (September 1982). "Post-menopausal concentrations of plasma oestradiol, oestrone, FSH and LH and of total urinary oestradiol and oestrone after a single sublingual dose of oestradiol-17 beta". Acta Endocrinol. 101 (1): 93–7. doi:10.1530/acta.0.1010093. PMID 6812348.
- ^ a b Rigg LA, Milanes B, Villanueva B, Yen SS (1977). "Efficacy of intravaginal and intranasal administration of micronized estradiol-17beta". J. Clin. Endocrinol. Metab. 45 (6): 1261–4. doi:10.1210/jcem-45-6-1261. PMID 591620.
- ^ Strecker JR, Lauritzen C, Goessens L (1979). "Plasma concentrations of unconjugated and conjugated estrogens and gonadotrophins following application of various estrogen preparations after oophorectomy and in the menopause". Maturitas. 1 (3): 183–90. PMID 228157.
- ^ a b c Whitehead MI, Townsend PT, Kitchin Y, Dyer G, Iqbal MJ, Mansfield MD, et al. (1980). "Plasma steroid and protein hormone profiles in postmenopausal women following topical administration of oestradiol 17
β ". In Mauvais-Jarvis P (ed.). Percutaneous Absorption of Steroids. Academic Press. p. 231. - ^ Schiff I, Tulchinsky D, Ryan KJ (1977). "Vaginal absorption of estrone and 17beta-estradiol". Fertil. Steril. 28 (10): 1063–6. doi:10.1016/S0015-0282(16)42855-4. PMID 908445.
- ^ Lauritzen C (December 1986). "Die Behandlung der klimakterischen Beschwerden durch vaginale, rektale und transdermale Ostrogensubstitution" [Treatment of disorders of the climacteric by vaginal, rectal and transdermal estrogen substitution]. Gynakologe (in German). 19 (4): 248–53. ISSN 0017-5994. PMID 3817597.
- ^ a b c Oriowo MA, Landgren BM, Stenström B, Diczfalusy E (April 1980). "A comparison of the pharmacokinetic properties of three estradiol esters". Contraception. 21 (4): 415–24. doi:10.1016/S0010-7824(80)80018-7. PMID 7389356.
- ^ Vermeulen A (1975). "Longacting steroid preparations". Acta Clin Belg. 30 (1): 48–55. doi:10.1080/17843286.1975.11716973. PMID 1231448.
- ^ Stege R, Gunnarsson PO, Johansson CJ, Olsson P, Pousette A, Carlström K (May 1996). "Pharmacokinetics and testosterone suppression of a single dose of polyestradiol phosphate (Estradurin) in prostatic cancer patients". Prostate. 28 (5): 307–10. doi:10.1002/(SICI)1097-0045(199605)28:5<307::AID-PROS6>3.0.CO;2-8. PMID 8610057.
- ^ Kuhnz W, Gansau C, Mahler M (September 1993). "Pharmacokinetics of estradiol, free and total estrone, in young women following single intravenous and oral administration of 17
β -estradiol". Arzneimittelforschung. 43 (9): 966–73. ISSN 0004-4172. PMID 8240460. - ^ Nichols KC, Schenkel L, Benson H (1984). "17 beta-estradiol for postmenopausal estrogen replacement therapy". Obstet Gynecol Surv. 39 (4): 230–45. doi:10.1097/00006254-198404000-00022. PMID 6717863.